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Scavenger receptor class B, type I (SRBI) is a key
regulator of high density lipoprotein (HDL) metabolism.
It facilitates the efflux of cholesterol from cells in pe-
ripheral tissues to HDL and mediates the selective up-
take of cholesteryl esters from HDL in the liver. We
investigated the effects of SRBI deficiency in the arte-
rial wall and in the liver using SRBI-deficient mice and
wild-type littermates fed a Western-type diet. The SRBI-
deficient mice showed massive accumulation of choles-
terol-rich HDL in the circulation, reflecting impaired
delivery to the liver. Strikingly, SRBI deficiency did not
alter hepatic cholesterol (ester) content nor did it affect
the expression of key regulators of hepatic cholesterol
homeostasis, including HMG-CoA reductase, the low
density lipoprotein receptor, and cholesterol 7-hydrox-
ylase. However, a 40% reduction in biliary cholesterol
content was observed, and the expression of ABCG8 and
ABCG5, ATP half-transporters implicated in the trans-
port of sterols from the liver to the bile, was attenuated
by 70 and 35%, respectively. In contrast to the situation
in the liver, SRBI deficiency did result in lipid deposi-
tion in the aorta and atherosclerosis. Vascular mRNA
analysis showed increased expression of inflammatory
markers as well as of genes involved in cellular choles-
terol homeostasis. Our data show that, although hepatic
cholesterol homeostasis is maintained upon feeding a
Western-type diet, SRBI deficiency is associated with
de-regulation of cholesterol homeostasis in the arterial
wall that results in an increased susceptibility to
atherosclerosis.
A low level of high density lipoprotein (HDL)1 is an impor-
tant risk factor for the development of atherosclerosis (1, 2).
Stimulation of reverse transport of cholesterol from cells of the
arterial wall to the liver is considered the mechanism by which
HDL exerts its anti-atherogenic properties (3). In addition,
interaction of HDL with the arterial wall directly protects
against oxidative stress and vascular inflammation (4).
An important mediator of HDL metabolism is scavenger
receptor class B, type I (SRBI) (5). SRBI is a multifunctional
receptor capable of binding a wide array of native and modified
lipoproteins. SRBI is abundantly expressed in liver and steroi-
dogenic tissues, where it mediates the selective uptake of cho-
lesteryl esters from HDL (6, 7). A definitive role for SRBI in
HDL metabolism and reverse cholesterol transport in vivo has
been demonstrated using different transgenic and knockout
mouse models. Hepatic overexpression of SRBI is accompanied
by decreased levels of HDL cholesterol (8, 9). Furthermore,
targeted inactivation of SRBI induced a 2-fold increase in
plasma cholesterol levels due to the accumulation of abnor-
mally large, heterogeneous HDL (10). When cross-bred onto the
apolipoprotein E knockout background, SRBI deficiency leads
to severe cardiac dysfunction and premature death (11, 12).
Hepatic overexpression of SRBI, on the other hand, protects
against the development of atherosclerosis (13).
In addition to the liver, SRBI is also expressed by cells within
the arterial wall, including endothelial cells, smooth muscle
cells, and macrophages (14–16). At least in macrophages, SRBI
has been implicated in the bi-directional flux of cholesterol and
phospholipids between HDL and the cell membrane (17, 18).
However, whether vascular SRBI plays a direct role in arterial
lipid homeostasis or in HDL-mediated anti-atherogenic effects
is currently unknown.
In this study, the differential effects of SRBI deficiency on
lipid metabolism and related gene expression in cells of the
liver and the arterial wall were evaluated in response to a
challenge with an atherogenic diet. We show that, despite an
impaired delivery of HDL cholesterol to the liver in SRBI/
mice, hepatic cholesterol homeostasis is maintained by pro-
cesses involving down-regulation of ABCG5/ABCG8 and up-
regulation of ABCG1. In contrast, SRBI deficiency in the arte-
rial wall results in de-regulation of vascular lipid homeostasis
and induction of inflammation culminating in atherosclerosis.
EXPERIMENTAL PROCEDURES
Mice—SRBI-deficient mice were kindly provided by Dr. M. Krieger
(10). Heterozygous SRBI-deficient mice were cross-bred to generate
wild-type (SRBI/), heterozygous (SRBI/), and homozygous
(SRBI/) progeny. The presence of the targeted and wild-type SRBI
alleles was assessed by PCR amplification of DNA extracted from tail
biopsies (primers 5-GAT-GGG-ACA-TGG-GAC-ACG-AAG-CCA-TTC-
T-3 and 5-TCT-GTC-TCC-GTC-TCC-TTC-AGG-TCC-TGA-3). Mice
were maintained on sterilized regular chow containing 4.3% (w/w) fat
and no cholesterol (RM3, Special Diet Services, Witham, UK). At 12–16
weeks of age, the diet was switched to a semi-synthetic high fat/high
cholesterol Western-type diet containing 15% (w/w) fat and 0.25% (w/w)
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cholesterol (Diet W, Hope Farms, Woerden, The Netherlands). After 20
weeks of feeding the Western-type diet, the mice were anesthetized, and
blood and gall bladder bile were collected for lipid analyses. Subse-
quently, a whole-body perfusion was performed using phosphate-buff-
ered saline containing 1 mM EDTA (4 °C, 100 mm of Hg) for 20 min.
After perfusion, the liver, aortic arch (from the base of the aorta to just
below the left subclavian artery), and heart plus aortic root were ex-
cised. The aortic arch and liver were frozen in liquid N2 and stored at
80 °C until RNA isolation. The heart plus aortic root were stored in
3.7% formalin. All experimental protocols were approved by the Ethics
Committee for animal experiments of Leiden University.
In Vivo Analysis of HDL Cholesteryl Ester Delivery to the Liver—
Human HDL was isolated by differential ultracentrifugation as de-
scribed by Redgrave et al. (19) and subsequently labeled with [3H]cho-
lesterol oleate (Amersham Biosciences) by exchange from donor
particles as reported previously (20). The radiolabeled HDL was in-
jected via the vena cava inferior of anesthetized mice. After 4 h of
circulation, blood was sampled, and the liver was excised. The associ-
ated radioactivity was determined in a Packard liquid scintillation
counter after combustion in a Packard sample oxidizer.
Lipid Analyses—Serum concentrations of cholesterol, cholesteryl es-
ters, and triglycerides were determined using enzymatic colorimetric
assays (Roche Applied Science). The distribution of cholesterol over the
different lipoproteins in serum was analyzed by fractionation of 30 l of
serum of each mouse using a Superose 6 column (3.2  30 mm, Smart-
system, Amersham Biosciences). Total cholesterol content of the efflu-
ent was determined using enzymatic colorimetric assays (Roche Ap-
plied Science), taking the efficiency of recovery from the column into
account. HDL was isolated from pooled sera by density-gradient ultra-
centrifugation, and cholesteryl ester, free cholesterol, triglyceride, and
phospholipid contents of the isolated HDL were determined as de-
scribed. The protein content of the HDL fractions was determined
according to Lowry et al. (21). Hepatic and biliary lipids were extracted
according to Bligh and Dyer (22). After dissolving the lipids in 2%
Triton X-100, the contents of cholesterol, cholesteryl ester, and triglyc-
erides in liver tissue were determined as described above and expressed
as nmol/mg of protein. Biliary bile salt and cholesterol concentrations
were determined according to Setchell et al. (23) and Gamble et al. (24),
respectively.
Assessment of Lesion Formation in the Aortic Root—Serial sections of
the aortic root were cut using a Leica CM3050S cryostat. The athero-
sclerotic lesion area was quantified in oil red O-stained cryostat sec-
tions using the Leica image analysis system, consisting of a Leica
DMRE microscope coupled to a video camera and Leica Qwin Imaging
software (Leica Ltd., Cambridge, England). Mean lesion area (in m2)
was calculated from 10 consecutive oil red O-stained sections, starting
at the appearance of the tricuspid valves.
Analysis of Gene Expression by Real-time Quantitative PCR—Total
RNA was extracted from liver and aortic arch by the acid guanidinium
thiocyanate-phenol chloroform extraction method according to Chomc-
zynski and Sacchi (25) in the presence of 0.2 mg/ml glycogen. cDNA was
synthesized from 0.5–1 g of total RNA using RevertAid™ Moloney
murine leukemia virus reverse transcriptase. mRNA levels were quan-
titatively determined on an ABI Prism® 7700 sequence detection sys-
tem (Applied Biosystems, Foster City, CA) using SYBR-green technol-
ogy according to manufacturer’s instructions. PCR primers (Table I)
were designed using Primer Express 1.5 Software using the manufac-
turer’s default settings (Applied Biosystems).
The level of mRNA expression for each gene of interest was calcu-
lated using the threshold cycle (Ct) value, i.e. the number of PCR
cycles at which the fluorescent signal during the PCR reaches a fixed
threshold. For each sample, both the Ct for the gene of interest and
for the housekeeping gene hypoxanthine-guanine phosphoribosyl-
transferase were determined to calculate Ct,sample (Ct,target gene 
Ct,housekeeping gene), thus normalizing the data and correcting for dif-
ferences in amount and/or quality between the different RNA sam-
ples. The expression levels were related to an external calibrator
consisting of a cDNA pool of different mouse organs (i.e. liver, spleen,
lung, muscle, and aorta, each represented equally). Subsequently,
Ct (Ct,sample  Ct,calibrator) was determined, and the relative
expression levels were calculated from 2Ct, according to the man-
ufacturer’s instructions (Applied Biosystems). mRNA expression
levels are, thus, indicated as arbitrary units  S.E.
Immunoblot Analysis—Liver homogenate was prepared by lysis in 50
mM Tris-HCl, 1% Triton X-100, 0.5% deoxycholate, 1% SDS containing
0.02 g/ml leupeptin, 0.02 g/ml aprotinin, and 0.02 g/ml trypsin
inhibitor. Cell debris was removed by centrifugation at 10,000 rpm for
10 min, and the protein concentration was determined according to
Lowry et al. (21). Equal amounts of protein were separated on 7.5%
SDS-PAGE gels and electrophoretically transferred to Protran nitrocel-
lulose membrane (Schleicher & Schnell). Immunolabeling was per-
formed using either rabbit polyclonal SRBI (anti-BI495 (26)) or murine
monoclonal ABCA1 (AC-10 (27)) as primary antibody and goat-anti-
rabbit IgG and goat-anti-mouse IgG (Jackson ImmunoResearch), re-
spectively, as secondary antibodies. Finally, immunolabeling was de-
tected by enhanced chemiluminescence (ECL, Amersham Biosciences).
Statistical Analyses—Statistical significant differences among the
means of the different groups of mice were tested using analysis of
variance and the Student-Newman-Keuls multicomparison test
(Graphpad Instat software, San Diego, CA).
RESULTS
A High Cholesterol Western-type Diet Results in Accumula-
tion of Cholesteryl Ester-rich HDL in Serum of SRBI-deficient
Mice—On chow diet, containing 4.3% fat and no cholesterol,
SRBI deficiency induced a 1.8-fold increase in total serum
cholesterol levels (p  0.001, Table II). Interestingly, this in-
crease in total cholesterol levels was mainly a result of a 3.2-
fold increase in free cholesterol (p  0.001, Table II). As indi-
cated in Fig. 1a, changes in serum cholesterol levels were
caused by a marked increase in the amounts of cholesterol
transported by HDL. So far these findings confirmed the role of
SRBI in determining circulating HDL levels (10). Subse-
quently, we challenged the SRBI-deficient mice with a West-
ern-type diet containing 15% fat and 0.25% cholesterol for a
period of 20 weeks. The length of the dietary period was chosen
such that effects on vascular function and atherosclerosis, if
TABLE I
Primers for real-time PCR analysis
Gene GenBank
TM
accession No. Forward primer Reverse primer
Amplicon
size
SR-BI NM_016741 GGCTGCTGTTTGCTGCG GCTGCTTGATGAGGGAGGG 63
ABCA1 NM_013454 GGTTTGGAGATGGTTATACAATAGTTGT TTCCCGGAAACGCAAGTC 96
ABCG1 NM_009593 AGGTCTCAGCCTTCTAAAGTTCCTC TCTCTCGAAGTGAATGAAATTTATCG 85
ABCG5 NM_031884 TGGCCCTGCTCAGCATCT ATTTTTAAAGGAATGGGCATCTCTT 81
ABCG8 NM_026180 CCGTCGTCAGATTTCCAATGA GGCTTCCGACCCATGAATG 64
LRPa NM_008512 TGGGTCTCCCGAAATCTGTT ACCACCGCATTCTTGAAGGA 95
ApoE NM_009696 AGCCAATAGTGGAAGACATGCA GCAGGACAGGAGAAGGATACTCAT 130
LDL receptor Z19521 CTGTGGGCTCCATAGGCTATCT GCGGTCCAGGGTCATCTTC 68
CYP7A1 NM_007824 CTGTCATACCACAAAGTCTTATGTCA ATGCTTCTGTGTCCAAATGCC 75
HMG-CoA reductase M62766 TCTGGCAGTCAGTGGGAACTATT CCTCGTCCTTCGATCCAATTT 69
CD36 L23108 GTTCTTCCAGCCAATGCCTTT ATGTCTAGCACACCATAAGATGTACAGTT 110
CD68 NM_009853 CCTCCACCCTCGCCTAGTC TTGGGTATAGGATTCGGATTTGA 118
VCAM-1a X67783 ACAAAACGATCGCTCAAATCG CGCGTTTAGTGGGCTGTCTATC 110
P-selectin M87861 GGTATCCGAAAGATCAACAATAAGTG GTTACTCTTGATGTAGATCTCCACACA 141
E-selectin M87862 CCCTGCCCACGGTATCAG CCCTTCCACACAGTCAAACGT 85
HPRTa J00423 TTGCTCGAGATGTCATGAAGGA AGCAGGTCAGCAAAGAACTTATAGC 91
a LRP, LDL receptor-related protein; HPRT, hypoxanthine-guanine phosphoribosyltransferase; VCAM-1, vascular cell adhesion molecule-1.
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present, could also be assessed. Remarkably, the atherogenic
diet resulted in a dramatic further accumulation of HDL cho-
lesterol, with only minor effects on VLDL cholesterol levels
(Fig. 1b). Upon dietary induction, the cholesterol distribution
in the heterozygous SRBI-deficient littermates was similar to
that of wild-type controls, except for a tendency toward slightly
increased VLDL cholesterol levels. Compositional lipid analy-
sis of HDL, isolated after 20 weeks Western-type diet, showed
that the free cholesterol content was 4.5% in HDL from wild
types and 9.6% in HDL from SRBI knockouts. Cholesteryl ester
contents were 18.8 and 32.7% in wild-type and SRBI-deficient
mice, respectively, whereas the corresponding percentages for
phospholipids amounted to 40.6 and 23.6%, respectively. There
was no effect of SRBI deficiency on the protein content of the
isolated HDL. Thus, SRBI deficiency in combination with diet-
induced hypercholesterolemia resulted in the accumulation of
large HDLs enriched in cholesteryl esters and free cholesterol
and depleted of phospholipids. There was no effect of SRBI
deficiency on serum triglyceride levels under both dietary
conditions.
Maintenance of Hepatic Lipid Homeostasis in SRBI-deficient
Mice—In wild-type mice, the liver is responsible for the re-
moval of the majority of the cholesteryl esters (CEs) from HDL.
When injected with 3H-labeled HDL, 31.3  4.5% of the in-
jected dose was recovered from the liver in wild-type mice 4 h
after administration. In the absence of SRBI, uptake of cho-
lesteryl esters was reduced by 90% to only 3.3  0.8% of the
injected dose (p  0.05). A similar value was found for 125I-
labeled tyramine cellobiose-labeled HDL, indicative for whole
particle uptake (data not shown), suggesting that in SRBI
knockout mice, the selective uptake is completely abolished.
Correction for the HDL-CE pool size indicated the HDL-CE
mass influx into the liver was reduced from 22.0  3.8 g of
HDL-CE/hour in wild-type mice to 4.1 0.7 g of HDL-CE/h in
SRBI knockout animals. Reduced delivery of HDL cholesteryl
esters to the liver is, thus, most likely the cause of the accu-
mulation of large cholesterol-enriched HDL particles in the
circulation of the SRBI-deficient mice (Table II, Fig. 1). Inter-
estingly, this did not affect the hepatic levels of free cholesterol,
cholesteryl esters, and triglycerides (Fig. 2a).
Real-time PCR was subsequently used to determine the ex-
pression of genes involved in maintaining liver cholesterol ho-
meostasis. In accordance with the observed similar hepatic
lipid levels, there was no significant effect on the mRNA ex-
pression levels of hepatic HMG-CoA reductase and of the LDL
receptor (Fig. 3), both of which are regulated by the hepatic
cholesterol content. Similarly, the expression of cholesterol 7-
hydroxylase was not affected. Other genes involved in hepatic
cholesterol metabolism, including CD36, scavenger receptor
class A, LDL receptor-related protein, and apolipoprotein E
(apoE) were also not affected by the absence of SRBI (Fig. 3).
Collectively, the data indicate that the expression of key regu-
lators in de novo cholesterol biosynthesis, cholesterol uptake
from native and modified lipoproteins, and cholesterol break-
down (28) are not affected by SRBI deficiency and reduced
delivery of HDL cholesterol to the liver.
SRBI deficiency, however, did coincide with an approximate
40% reduction in biliary cholesterol content normalized to bile
salt content (Fig. 2b). Two members of the ABCG subfamily of
ABC transporters that have recently been implicated in the
efflux of sterols from the liver into the bile are the co-operating
half-transporters ABCG5 and ABCG8 (29). Interestingly,
ABCG5 and ABCG8 mRNA expression was attenuated by 35
and 70% (p  0.05), respectively, in mice lacking SRBI as
compared with wild-type mice (Fig. 3). Other members of the
family of ABC transporters implicated in sterol trafficking are
ABCA1 and ABCG1 (30, 31). SRBI deficiency did not affect
ABCA1 mRNA expression. For most genes mRNA expression
strongly correlates with protein expression. ABCA1 mRNA
TABLE II
Effect of SRBI deficiency on serum lipid levels
Serum lipids were measured in SRBI/, SRBI/, and SRBI/ mice maintained on a chow diet; and after feeding a high cholesterol
Western-type diet (WTD) for 20 weeks. Data represent the means  S.E. Statistically significant difference: compared to SRBI/ mice is shown
in the table footnotes.
Mice Time Diet n Triglycerides Total cholesterol Free cholesterol Cholesteryl esters HDL cholesteryl esters
weeks mg/dl mg/dl mg/dl mg/dl mg/dl
SRBI/ 0 Chow 6 108  15 93  7 24  1 70  6 49.1  6
20 WTD 6 98  8 122  12 28  3 94  10 61.5  8
SRBI/ 0 Chow 5 118  20 139  6a 36  3a 103  4a 81.2  5a
20 WTD 5 97  12 185  8b 47  1b 138  7a 86.8  5c
SRBI/ 0 Chow 5 99  4 167  10b 81  3b 88  7a 76  7a
20 WTD 5 96  11 322  20b 150  20b 172  9b 138  10b
a p  0.01.
b p  0.001.
c p  0.05.
FIG. 1. Effect of SRBI deficiency on the plasma cholesterol
distribution. Blood samples were drawn after an overnight fast while
feeding regular chow diet (a) and after 20 weeks of feeding a high
cholesterol Western-type diet (WTD) (b). Sera from individual mice
were loaded onto a Superose 6 column, and fractions were collected.
Fractions 3–7 represent VLDL; fractions 8–14 represent LDL; fractions
15–19 represent HDL. The distribution of cholesterol over the different
lipoproteins in SRBI/ (E), SRBI/ (Œ), and SRBI/ () is shown.
Values represent the mean of 5–6 mice. S.E. are shown only for frac-
tions containing the top of the VLDL, LDL, and HDL peaks.
FIG. 2. Effect of SRBI deficiency on hepatic and biliary cho-
lesterol content. Hepatic (a) and biliary (b) cholesterol content was
analyzed in SRBI/, SRBI/, and SRBI/ mice after 20 weeks
feeding of a high cholesterol Western-type diet. Values represent the
mean  S.E. of 5–6 mice. *, statistically significant difference of p 
0.05 compared with SRBI/ mice.
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levels, however, appear to be a poor predictor for protein ex-
pression levels (27). Therefore, in addition to ABCA1 mRNA
analysis, the protein expression was determined by immuno-
blotting. In accordance with the mRNA data, SRBI deficiency
did not influence the protein expression of ABCA1 (Fig. 4).
Although ABCA1 expression was not affected, ABCG1 expres-
sion was stimulated 4.3-fold (p  0.05) in the absence of SRBI
(Fig. 3), suggesting a compensatory function of ABCG1 in
maintaining cholesterol homeostasis in the livers of mice lack-
ing SRBI.
Lipid Deposition and Vascular Inflammation in SRBI-defi-
cient Mice—Although the liver has several established mecha-
nisms to maintain lipid homeostasis, the arterial wall mainly
relies on cholesterol efflux pathways to prevent its accumula-
tion. Vascular tissue was analyzed after 20 weeks of feeding the
mice a Western-type diet to examine the effects of SRBI dis-
ruption and hypercholesterolemia on arterial wall morphology
and function. As shown in Fig. 5, SRBI deficiency led to a
72-fold (p 0.001) increase in mean atherosclerotic lesion area,
i.e. from 0.8  0.4  103 m2 in wild-type mice to 60  6  103
m2 in mice lacking SRBI. Lesions consisted primarily of fatty
streaks with oil red O-positive lipid-laden macrophages (Fig.
5b). Heterozygous SRBI-deficient mice did not display any lipid
deposition in the arterial wall, in line with the minor effects on
serum HDL cholesterol levels when compared with wild-type
littermates.
Both de-regulation of cholesterol homeostasis and inflamma-
tory processes play a pivotal role in the pathogenesis of ather-
osclerosis (32). Therefore, the effect of SRBI deficiency on the
mRNA expression of genes involved in these two processes was
analyzed. As shown in Fig. 6a, SRBI deficiency led to a signif-
icant induction of genes implicated in adhesion and transendo-
thelial migration of monocytes, including P-selectin (2-fold,
p  0.05), E-selectin (4-fold, p  0.05), and vascular cell adhe-
sion molecule-1 (2-fold, p  0.01). The induction of these genes
coincided with a 2-fold (p  0.05) increase in CD68 expression,
indicative of an increase in the amount of macrophages present
within the arterial wall. The observed increase in inflamma-
tory markers may, thus, be directly related to atherosclerotic
lesion development. SRBI deficiency also led to a significant
induction of genes implicated in cholesterol efflux from macro-
phages, including apoE (2-fold, p  0.05), ABCA1 (3-fold, p 
0.001), and ABCG1 (7-fold, p 0.001) (Fig. 6b). The increase in
expression of these genes was more pronounced than the in-
crease in CD68 expression, suggesting cellular activation in
addition to infiltration. ApoE and ABCA1 as well as ABCG1 are
cholesterol-responsive genes that show increased expression
upon cholesterol loading of macrophages. Importantly, despite
the up-regulation of apoE, ABCA1, and ABCG1, vascular in-
flammation and atherosclerotic lesion development could not
be prevented in SRBI-deficient mice challenged with an athero-
genic diet.
DISCUSSION
SRBI is an important mediator of HDL metabolism. The
availability of gene-targeted mice that lack functional SRBI
expression enabled us to study its role in the maintenance of
cellular cholesterol homeostasis in the liver, the site of choles-
terol disposal, and in the arterial wall, the site where patho-
logical cholesterol accumulation occurs.
As previously shown by Rigotti et al. (10), SRBI deficiency
resulted in elevated circulating levels of HDL cholesterol.
When injected with 3H-labeled HDL as a tracer of HDL metab-
olism, SRBI-deficient mice showed a dramatic reduction of the
FIG. 3. Effect of SRBI deficiency on hepatic mRNA expression of genes involved in lipid homeostasis. mRNA levels of the indicated
genes in livers of SRBI/, SRBI/, and SRBI/ mice were quantified using real-time PCR with SYBR-green detection after 20 weeks high
cholesterol Western-type diet feeding. Values are in arbitrary units (A.U.) and represent the mean  S.E. of 5–6 mice. *, statistically significant
difference of p  0.05 compared with SRBI/ mice. **, statistically significant difference of p  0.01 compared with SRBI/ mice.
FIG. 4. Protein expression of SRBI and ABCA1 in livers of
SRBI/, SRBI/, and SRBI/ mice after 20-week Western-
type diet feeding. Hepatic lysates (75 and 25 g for detection of SRBI
and ABCA1, respectively) were separated on non-reducing 7.5% SDS-
PAGE and immunoblotted with anti-BI495 or AC-10 for detection of
SRBI or ABCA1, respectively.
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hepatic uptake of HDL cholesteryl esters, indicating that the
accumulation of HDL cholesterol within the circulation is a
direct consequence of an impaired delivery to the liver. Fur-
thermore, we show that SRBI deficiency combined with a high
fat/high cholesterol Western-type diet resulted in an even more
dramatic accumulation of HDL cholesterol in the circulation.
The amount of cholesterol (ester) in HDL was increased rela-
tive to the phospholipid content. This increase in core-surface
lipid ratio would indicate the presence of larger particles rather
than an increase in particle number, which is supported by the
fast protein liquid chromatography data (Fig. 1). Interestingly,
not only the amount of cholesteryl esters in HDL increased but
also that of free cholesterol. The conversion of cholesterol in
HDL into cholesteryl esters is mediated by the plasma enzyme
lecithin cholesterol acyltransferase (33). Kosek et al. (34) have
previously shown that lecithin cholesterol acyltransferase is
subject to product inhibition. Because HDL from SRBI-defi-
cient mice is highly enriched in cholesteryl esters, reactivity
with lecithin cholesterol acyltransferase might be reduced be-
cause the cholesteryl ester products cannot be effectively re-
moved from the active site of the enzyme, hence, resulting in
the accumulation of free cholesterol.
Although the delivery of cholesteryl esters to the liver is
reduced in the absence of SRBI, there was no effect on hepatic
lipid content in SRBI-deficient mice challenged with a West-
ern-type diet. Mardones et al. (35) have previously shown that
on a regular chow diet, hepatic cholesterol levels in SRBI-
deficient mice are even slightly increased. We show that on a
Western-type diet SRBI deficiency also did not alter the hepatic
expression of HMG-CoA reductase, cholesterol 7-hydroxylase,
LDL receptor, CD36, scavenger receptor class A, LDL receptor-
related protein, and apoE. Thus, the decreased influx of cho-
lesterol due to absence of SRBI was not compensated for by
changes in expression of key regulators of hepatic cholesterol
synthesis, cholesterol conversion into bile acids, or liver uptake
of native or modified lipoproteins. This is in accordance with
the recent observation that a total absence of HDL in mice due
to ABCA1 deficiency is also not associated with altered hepatic
cholesterol metabolism (36). In contrast to ABCA1-deficient
mice, however, we found that SRBI-deficient mice did exhibit a
reduction in biliary cholesterol. SRBI-deficient mice on chow
diet also display reduced biliary cholesterol secretion rates (35),
whereas mice overexpressing SRBI have increased secretion
rates (13, 37).
Although the hepatic SRBI expression level appears to be
associated with the level of biliary cholesterol secretion, the
exact nature of this relationship is unknown. HDL has been
suggested to provide an important source of biliary cholesterol
(20, 38), and impaired delivery of HDL cholesterol to the liver
might, thus, affect the availability of cholesterol for excretion
into the bile. However, recent studies have unequivocally dem-
onstrated that the absence of HDL does not influence biliary
cholesterol secretion rates in mice (36, 39). Alternatively, an
increasing amount of evidence suggests a direct role for hepatic
FIG. 5. SRBI deficiency induces atherosclerotic lesion development. Formation of atherosclerotic lesions was determined at the aortic
root in SRBI/, SRBI/, and SRBI/mice after 20 weeks of feeding a high cholesterol Western-type diet. a, quantification of the mean lesion
area. Values represent the mean  S.E. of 5–6 mice. b, representative photomicrographs of oil red O-stained cross-sections of the aortic root at the
level of the tricuspid valves. Original magnification 50. ***, statistically significant difference of p  0.001 compared with SRBI/ mice.
FIG. 6. SRBI deficiency induces mRNA expression of inflammatory markers (a) and of genes involved in lipid homeostasis (b) in
the aortic arch. mRNA levels of the indicated genes in aortae of SRBI/, SRBI/, and SRBI/ mice were quantified using real-time PCR
with SYBR-green detection after 20 weeks of high cholesterol Western-type diet feeding. Values represent the mean  S.E. of 5–6 mice. *,
statistically significant difference of p  0.05 compared with SRBI/ mice; **, p  0.01; ***, p  0.001.
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SRBI in the targeting of (HDL-derived) cholesterol into path-
ways of biliary secretion. In polarized hepatocytes, SRBI is
localized to both the sinusoidal membrane and the canalicular
membrane (13, 40). Thus, SRBI may mediate the transfer of
HDL cholesterol from the basal to the apical membrane under
normal conditions. In addition, we found that mRNA expres-
sion levels of two half-size ATP binding cassette transporters,
ABCG5 and ABCG8, were decreased in livers of SRBI-deficient
mice fed a Western-type diet. Their relevance in sterol trans-
port has been established in -sitosterolemia, a rare autosomal
disorder characterized by mutations in ABCG5 and ABCG8
(41, 42), that results in highly elevated plasma levels of plant
sterols and cholesterol as a consequence of intestinal hyperab-
sorption and impaired biliary secretion. In a very recent study,
Yu et al. (29) demonstrate that simultaneous overexpression of
ABCG5 and ABCG8 strongly promotes biliary cholesterol se-
cretion in mice. Furthermore, Berge et al. (42) show that feed-
ing wild-type mice a 2% cholesterol diet results in a compen-
satory up-regulation of hepatic ABCG5 and ABCG8, probably
to allow rapid secretion of dietary cholesterol into the bile. In
view of this, it is possible that the impaired biliary cholesterol
secretion in SRBI-deficient mice is a result of attenuated he-
patic expression of ABCG5 and ABCG8.
In addition to ABCG5 and ABCG8, other ABC transporters
including ABCG1 and ABCA1 may participate in maintaining
cholesterol homeostasis in the liver. We did not observe any
effect of SRBI deficiency on hepatic ABCA1 expression. ABCG1
expression, however, was markedly increased in SRBI-defi-
cient mice. The physiological function of ABCG1 in the liver is
not well defined. In macrophages, the expression of ABCG1 is
induced by cholesterol-loading and LXR agonists, which in turn
is associated with enhanced cholesterol efflux (43). Conversely,
blockade of the ABCG1 expression using antisense oligonucleo-
tides inhibits cholesterol efflux. Because ABCG1 is primarily
localized intracellularly (43), it is thought that it facilitates the
translocation of phospholipids and cholesterol from intracellu-
lar compartments to the plasma membrane (30). Adenovirus-
mediated overexpression of ABCG1 in mice results in a signif-
icant reduction of serum HDL-cholesterol levels, indicating an
important role for ABCG1 in HDL cholesterol metabolism (44).
Increased expression of ABCG1 in livers of SRBI-deficient mice
might offer an alternative route for removal of HDL cholesterol.
Although the liver is able to maintain lipid homeostasis in
the absence of SRBI by reducing cholesterol excretion into the
bile, SRBI deficiency did result in a dramatic de-regulation of
lipid homeostasis and induction of vascular inflammation in
the arterial wall and in atherosclerotic lesion development.
Remarkably, no lesions were observed in heterozygous SRBI-
deficient mice. This would indicate that the single allele is
sufficient to prevent atherosclerosis and, thus, that agents that
establish a mild increase in SRBI expression might have the
same effect. In what respect does vascular tissue differ from
liver tissue, in that the absence of SRBI shows such deleterious
effects in the former and not in the latter? First, the liver has
multiple pathways at its disposal (uptake, endogenous synthe-
sis, regulated storage, re-secretion, and excretion) to stabilize
cellular lipid homeostasis. In contrast, vascular tissue lipid
homeostasis is dependent solely on its efflux capacity. Cellular
cholesterol efflux rates correlate with the level of SRBI expres-
sion (17, 18, 45), suggesting that vascular SRBI may be directly
involved in this process. The absence of SRBI from macro-
phages and smooth muscle cells of the arterial wall might,
therefore, have resulted in impairment of the cholesterol efflux
capacity and induction of foam cell formation. Remarkably,
increased expression of other genes involved in cholesterol
efflux, including apoE, ABCA1, and ABCG1, failed to prevent
the formation of lipid-laden macrophages in the arterial wall of
SRBI-deficient mice, underscoring the total derailment of lipid
homeostasis in this tissue. As for ABCA1, it is known that it
binds large cholesteryl ester-rich HDL with low affinity and
mainly effluxes lipid to lipid-free or poorly lipidated apolipopro-
teins (46, 47). Under the dietary conditions studied, the large
cholesteryl ester-rich HDL that circulates in the SRBI-deficient
mice was probably also unable to induce the efflux of choles-
terol via alternative pathways.
Second, SRBI mediates the uptake of -tocopherol, a cellular
antioxidant (48), and binding of HDL to SRBI on endothelial
cells stimulates endothelial nitric-oxide synthase, an enzyme
that is critical for vascular function (49). The absence of SRBI
locally in the arterial wall might, thus, also directly have af-
fected vascular function and the availability of cellular
antioxidants.
Finally, the large cholesteryl ester-rich HDL particles that
accumulate in SRBI-deficient mice might exhibit reduced anti-
oxidant and anti-inflammatory potential. The anti-oxidant and
anti-inflammatory properties of HDL are primarily dependent
on its content of anti-inflammatory proteins such as platelet-
activating factor acylhydrolase, paraoxonase, and apolipopro-
tein J and the pro-inflammatory proteins serum amyloid A and
ceruloplasmin (4). Elevated levels of HDL prevent vascular
inflammation in humans (3) and in mouse models of athero-
sclerosis (50). The observed susceptibility of SRBI-deficient
mice to atherosclerosis, despite highly elevated levels of HDL,
demonstrates that not only its concentration but also its spe-
cific composition are of importance for the anti-atherogenic
properties of HDL. The fact that HDL isolated from patients
with coronary artery disease but with normal blood lipid levels
also displays reduced anti-oxidant potential illustrates the clin-
ical relevance of this finding (4).
In conclusion, SRBI deficiency differentially affects lipid me-
tabolism in cells of the liver and those of the arterial wall; in
liver, cholesterol homeostasis is maintained by down-regula-
tion of the capacity for cholesterol secretion into the bile,
whereas in the arterial wall, SRBI deficiency is associated with
a severe de-regulation of cholesterol homeostasis and induction
of inflammation and atherosclerosis.
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